Recent News

• 01.23.2026 - Corvus Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares, Generating Gross Proceeds of Approximately $201M
• 01.22.2026 - Corvus Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock
• 01.20.2026 - Corvus Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
• 01.16.2026 - Corvus Pharmaceuticals to Announce Results from Cohort 4 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
• 11.04.2025 - Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2025 Financial Results
• 11.03.2025 - Corvus Pharmaceuticals to Present Final Data from Soquelitinib Phase 1/1b T Cell Lymphoma Trial at the 67th American Society of Hematology Annual Meeting & Exposition

Recent Filings

• 01.23.2026 - 424B5 Prospectus [Rule 424(b)(5)]
• 01.23.2026 - 8-K Current report
• 01.21.2026 - S-3MEF Registration adding securities to prior Form S-3 registration [Rule 462(b)]
• 01.20.2026 - 8-K Current report
• 01.20.2026 - EX-99.1 EX-99.1
• 01.20.2026 - 424B5 Prospectus [Rule 424(b)(5)]
• 01.20.2026 - 8-K Current report
• 12.08.2025 - 4 Statement of changes in beneficial ownership of securities
• 12.08.2025 - 4 Statement of changes in beneficial ownership of securities
• 12.08.2025 - 4 Statement of changes in beneficial ownership of securities